Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606334 | 1.00 | POLB (0.41) | POLBL3MBTL1KMT2AMEN1GAA | |
| SCHEMBL3546415 | 1.00 | POLB (0.41) | POLBL3MBTL1KMT2AMEN1GAA | |
| SCHEMBL15018804 | 0.85 | L3MBTL1 (0.37) | L3MBTL1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL8491831 | 0.80 | POLB (0.41) | POLBL3MBTL1KMT2AMEN1GAA | |
| SCHEMBL13271827 | 0.75 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1DDB1CRBN | |
| SCHEMBL1787415 | 0.75 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1DDB1CRBN | |
| SCHEMBL1787412 | 0.75 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1DDB1CRBN | |
| SCHEMBL1787411 | 0.75 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1DDB1CRBN | |
| SCHEMBL4542699 | 0.73 | ALDH1A1 (0.39) | L3MBTL1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL8892945 | 0.73 | ALDH1A1 (0.39) | L3MBTL1KMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-108137586-B | Novel imidazo [4,5-c ] quinoline and imidazo [4,5-c ] [1,5] naphthyridine derivatives as LRRK2 inhibitors | 辉瑞大药厂 | 2021-04-13 | — | — | CN | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017046675-A1 | NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | LRRK2, PARK7, SNCA | POLB 249/4885L3MBTL1 321/4885KMT2A 499/4885 |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | LRRK2, PARK7, SNCA | POLB 224/4885L3MBTL1 300/4885KMT2A 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.